YARW logo

YARROW BIOSCIENCE INC

YARWNASDAQ
🏆 #5480 by market capUS Equity
$24.20▲ $0.39 (+1.60%)
Live
🔔
Track YARW
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▼ 15.3%
14d▼ 4.2%
30d▼ 35.0%
ytd▼ 16.6%
1y▲ 47.8%
🏦Market Cap
$416,143
Small Cap
📈Revenue Growth (YoY)
+13.8%
Healthy
📊Gross Margin
97.5%
High
💵FCF Margin
-3513.1%
Thin
⚖️P/S Ratio
0.9x
Cheap
Otter Score
76
Good

Trading Snapshot

Day Range
$23.82 – $24.38
52-Week Range
$16.00 – $46.95
Volume
$3.20B
Avg Volume
$2.90B
Shares Outstanding
17,196
Next Earnings
Nov 20, 2026

Fundamentals Snapshot

Annual Revenue
$570,000
Last Q Revenue
$97,000
P/E Ratio
-1.0
P/S Ratio
0.9x
EPS (TTM)
$-21.81
Dividend Yield
82.68%
Dilution (1yr)
−21.8%

Why Investors Own YARW

  • ✓High-growth profile — revenue up +37.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 51% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

YARW logo

YARROW BIOSCIENCE INC

YARW
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$570K▲ +13.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.0%▼ −4.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$30M▼ −31.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −2.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
666K▼ −21.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24M▲ +$4M YoY
StockOtter · stockotter.space

About YARROW BIOSCIENCE INC

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$23.90
▼ −1.2% Downside
High Target$29.57
Low Target$19.83
Based on 20 analysts

Latest News & Updates

🚀
Barron’s·2h ago

YARROW BIOSCIENCE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift YARW price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

YARROW BIOSCIENCE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.